Juan Miguel Mosquera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Juan Miguel Mosquera has a total of 969 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Sboner
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
112 shared publications - Olivier Elemento
Cornell Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, USA
109 shared publications - Michael Sigouros
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
85 shared publications - Himisha Beltran
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
81 shared publications - Vincenza Conteduca
Unit of Medical Oncology and Biomolecular Therapy and CREATE Center for Research and Innovation in Medicine, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy
51 shared publications - Bhavneet Bhinder
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA
50 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (19)
Deep learning–based histologic classifiers enable molecular subtyping of metastatic prostate cancer
Metastatic prostate cancer is a clinically and molecularly heterogeneous disease. Under the selective pressure of androgen receptor–directed (AR-directed) therapies, resistant phenotypes frequently emerge, posing significant diagnostic and therapeutic challenges. Neuroendocrine prostate cancer (NEPC) is a clinically important phenotype characterized by lineage plasticity, neuroendocrine features, visceral metastases, and poor prognosis. Accurate diagnosis of NEPC remains difficult owing to its histologic and molecular complexity but has high clinical relevance. In this study, we developed a deep learning model that leverages interpretable cellular features to improve feature extraction from H&E-stained tissue sections (NEURAL-PC). By incorporating a multiple-instance learning framework, NEURAL-PC enables robust NEPC classification solely from H&E tumor images, achieving an area under the receiver operating characteristic curve of 0.921 in independent external validation. In addition to its diagnostic utility, NEURAL-PC provides prognostic information that enables further subclassification of advanced prostate cancer across diverse datasets, supporting its strong prognostic value and generalizability. Broadly, our work highlights a hybrid approach that integrates features across different domains, offering a promising strategy for developing reliable deep learning tools in pathology. Built on this framework, NEURAL-PC represents an extensively validated diagnostic and prognostic model for advanced prostate cancer.
- 6 August 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (19)
Open AccessDeep learning–based histologic classifiers enable molecular subtyping of metastatic prostate cancer
Metastatic prostate cancer is a clinically and molecularly heterogeneous disease. Under the selective pressure of androgen receptor–directed (AR-directed) therapies, resistant phenotypes frequently emerge, posing significant diagnostic and therapeutic challenges. Neuroendocrine prostate cancer (NEPC) is a clinically important phenotype characterized by lineage plasticity, neuroendocrine features, visceral metastases, and poor prognosis. Accurate diagnosis of NEPC remains difficult owing to its histologic and molecular complexity but has high clinical relevance. In this study, we developed a deep learning model that leverages interpretable cellular features to improve feature extraction from H&E-stained tissue sections (NEURAL-PC). By incorporating a multiple-instance learning framework, NEURAL-PC enables robust NEPC classification solely from H&E tumor images, achieving an area under the receiver operating characteristic curve of 0.921 in independent external validation. In addition to its diagnostic utility, NEURAL-PC provides prognostic information that enables further subclassification of advanced prostate cancer across diverse datasets, supporting its strong prognostic value and generalizability. Broadly, our work highlights a hybrid approach that integrates features across different domains, offering a promising strategy for developing reliable deep learning tools in pathology. Built on this framework, NEURAL-PC represents an extensively validated diagnostic and prognostic model for advanced prostate cancer.
- Open Access
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eadz3351
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.
- 26 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (26) , eadz3351
Open AccessPatient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities
We developed a pan-cancer patient-derived organoid (PDO) platform comprising 220 PDOs from 191 patients across 15 cancer types to advance functional precision oncology. Comprehensive characterization demonstrated high fidelity to parent tumors, with 93% histopathology concordance, 80% median genomic concordance for driver mutations, and a 0.85 median gene expression correlation. Expression profiles remained largely stable over 10 passages, ensuring reproducibility for long-term screening. Clonality analysis showed that 85% of dominant tumor clones were preserved, with genomic concordance directly reflecting clonal similarity. Even PDOs with lower concordance retained key oncogenic drivers, validating their utility as disease models. Functional assays revealed that 58% of PDOs from patients ineligible for US Food and Drug Administration–approved poly(adenosine 5′-diphosphate–ribose) polymerase inhibitors were sensitive to talazoparib, linked to DNA damage repair alterations. Furthermore, combination screens identified agents that overcome resistance, particularly in TP53 -mutant models. Our platform enables the investigation of targeted therapies and molecular drivers of drug sensitivity, providing translational insights for personalized treatment beyond current biomarker guidelines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of inhibitors tested in HTDS alone or in combination with gefitinib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of inhibitors tested in HTDS alone or in combination with gefitinib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S4 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
PDTO breast media composition.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
PDTO breast media composition.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of primers and vectors used in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of primers and vectors used in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
Table S6 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
IC50 values (µM) obtained for tested inhibitors in breast PDTO lines.